GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (NAS:AKTX) » Definitions » Shiller PE Ratio

Akari Therapeutics (Akari Therapeutics) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Akari Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Akari Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Akari Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Shiller PE Ratio Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akari Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Akari Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Shiller PE Ratio falls into.



Akari Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Akari Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Akari Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.827/131.7762*131.7762
=-0.827

Current CPI (Mar. 2024) = 131.7762.

Akari Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -17.000 98.326 -22.783
201403 -80.000 99.695 -105.744
201406 -80.000 100.560 -104.834
201409 -6.082 100.428 -7.980
201412 -20.000 99.070 -26.603
201503 -4.000 99.621 -5.291
201506 -4.000 100.684 -5.235
201509 -120.000 100.392 -157.515
201512 40.000 99.792 52.820
201603 -5.070 100.470 -6.650
201606 -20.000 101.688 -25.918
201609 -0.710 101.861 -0.919
201612 -20.000 101.863 -25.873
201703 -20.000 102.862 -25.622
201706 -0.543 103.349 -0.692
201709 -20.000 104.136 -25.309
201712 -20.000 104.011 -25.339
201803 -1.755 105.290 -2.196
201806 -20.000 106.317 -24.789
201809 -4.701 106.507 -5.816
201812 -4.445 105.998 -5.526
201903 -3.220 107.251 -3.956
201906 -5.124 108.070 -6.248
201909 -2.603 108.329 -3.166
201912 -7.304 108.420 -8.877
202003 -2.977 108.902 -3.602
202006 -4.956 108.767 -6.004
202009 0.539 109.815 0.647
202012 -13.842 109.897 -16.598
202103 -3.035 111.754 -3.579
202106 -2.259 114.631 -2.597
202109 -0.625 115.734 -0.712
202112 -2.490 117.630 -2.789
202203 -1.932 121.301 -2.099
202206 -1.914 125.017 -2.017
202212 0.000 125.222 0.000
202303 0.264 127.348 0.273
202306 -0.950 128.729 -0.972
202312 0.000 129.419 0.000
202403 -0.827 131.776 -0.827

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Akari Therapeutics  (NAS:AKTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Akari Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics (Akari Therapeutics) Business Description

Traded in Other Exchanges
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.
Executives
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
David Byrne director C/O AKARI THERAPEUTICS, PLC, 24 WEST 40TH STREET, 8TH FLOOR, NEW YORK NY 10018
Robert M Shaw officer: General Counsel and Secretary C/O BIOTECHNOLOGY GENERAL CORP, ONE TOWER CENTER BLVD 14TH FLR, EAST BRUNSWICK NJ 08816
Clive Richardson director, officer: COO C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Rpc Pharma Ltd 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Ray Prudo director, 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Stuart Ungar director, 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
James Hill director, 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Mark S Cohen director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Gur Roshwalb director, officer: Chief Executive Officer C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Amos Eiran director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Lau Johnson Yiu Nam director

Akari Therapeutics (Akari Therapeutics) Headlines

From GuruFocus

Akari Therapeutics to Present at Biotech Showcase� 2023

By Stock market mentor Stock market mentor 01-04-2023

Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

By Value_Insider Value_Insider 11-22-2022